Table 2 Adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) v3.0

From: Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

  All grades Grade 3 or 4
Adverse event n (%) n (%)
Stomatitis/oral mucositis 17 (63%) 2 (7%)
Pain 16 (59%) 4 (15%)
Rash 14 (52%) 1 (4%)
Nausea 12 (44%) 0 (0%)
Diarrhoea 12 (44%) 1 (4%)
Infections 11 (41%) 7 (26%)
Fatigue 10 (37%) 1 (4%)
Cough 9 (33%) 0 (0%)
Anorexia 8 (30%) 1 (4%)
Vomiting 8 (30%) 0 (0%)
Pruritus 7 (26%) 0 (0%)
Oedema 7 (26%) 0 (0%)
Hyperglycaemia 6 (22%) 3 (11%)
Weight loss 6 (22%) 0 (0%)
Epistaxis 6 (22%) 0 (0%)
Anaemia 5 (19%) 3 (11%)
Hypercholesterolaemia 5 (19%) 0 (0%)
Hypokalaemia 5 (19%) 1 (4%)
Taste alteration 4 (15%) 0 (0%)
Pneumonitis 4 (15%) 1 (4%)
Dry skin 4 (15%) 0 (0%)
Nail changes 4 (15%) 0 (0%)
Insomnia 4 (15%) 0 (0%)
Constipation 3 (11%) 1 (4%)
Headache 3 (11%) 0 (0%)
Neutropenia 2 (7%) 0 (0%)
Thrombocytopenia 2 (7%) 1 (4%)
Flu-like syndrome 2 (7%) 0 (0%)
Thromboembolism 2 (7%) 2 (7%)
Ocular toxicity 2 (7%) 0 (0%)